FIT Biotech Oy
Company announcement, March 15, 2018 at 12:30 EET
FIT Biotech's Review of Operations and Financial Statement 2017 published
FIT Biotech's Review of Operations and Financial Statement for the year 2017 have been published today.
The Review of Operations and Financial Statement is available in PDF format in Finnish and English as an appendix to this release and on the company's web site at www.fitbiotech.com in section Investors/Financial-reports/Annual-reports.
FIT Biotech Oy
CEO Erkki Pekkarinen, tel. +358 44 027 0080
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000
FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies its GTU® technology in its development projects, which at the time include gene-based treatments, genetic vaccines and research collaboration. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech K-shares are listed on the First North Finland market maintained by Nasdaq Helsinki Ltd.
DISTRIBUTION:
Nasdaq Helsinki
Principal media
www.fitbiotech.com